WideCells Group

Notice of General Meeting

News Release | News Room

WideCells Group PLC (‘WideCells Group’ or ‘the Group’)


Notice of General Meeting


WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, announces that a General Meeting (‘GM’) will be held on Thursday 15 November at 10:00am at the offices of Fladgate LLP, 16 Great Queen St, London WC2B 5DG. The GM has been called for the purpose of considering and, if thought fit, passing resolutions in connection with the Financing Agreement announced on 27 September 2018.  A Notice of GM is being posted to shareholders today and will shortly be available to view on the company’s website www.widecellsgroup.com.




For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:


WideCells Group

CEO – João Andrade

Tel:  +44 (0)161 920 7953

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar 

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR – Isabel de Salis & Priit Piip 

Tel: +44 (0) 20 7236 1177


Notes to Editors


WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable.  This is delivered through three divisions: 

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.
  • WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.


Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of cord blood. 
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.
  • 82 illnesses can currently be treated using stem cell procedures.
  • Despite initial collection and storage often costing no more than a few £thousands, actual treatment can cost in the £hundreds of thousands – before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals. 


This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).